Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials

Marco Miroddi, Carmelo Sterrantino, Ilaria Simonelli, Giorgio Ciminata, Robert S. Phillips, Gioacchino Calapai

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The anti-Epidermal Growth Factor Receptor monoclonal antibodies (anti-EGFR MoAbs) are beneficial in the treatment of wild type (WT) KRAS colorectal cancer, but are burdened by serious toxicities. We conducted a systematic review and meta-analysis to determine incidence and relative risk (RR) of severe and life-threatening diarrhoea and mucositis in colorectal cancer patients and WT-KRAS subpopulation. PubMed and Embase were searched for trials comparing the same therapeutic regimens with or without anti-EGFR for colorectal cancer. Data on severe and life-threatening diarrhoea and mucositis were extracted from 18 studies involving 13,382 patients. Statistical analyses calculated incidence of AEs, RRs and 95% confidence intervals by using either random or fixed effects models. Patients receiving anti-EGFR MoAbs showed an increased risk of diarrhoea (RR: 1.66, CI 1.52-1.80) and mucositis (RR: 3.44, CI 2.66-4.44). The risk was similar among WT-KRAS patients. Prevention and risk reduction strategies of these AEs are mandatory to optimize clinical outcomes.

Original languageEnglish
Pages (from-to)355-371
Number of pages17
JournalCritical Reviews in Oncology/Hematology
Volume96
Issue number2
DOIs
Publication statusPublished - Oct 25 2014

Fingerprint

Mucositis
Meta-Analysis
Colorectal Neoplasms
Diarrhea
Randomized Controlled Trials
Monoclonal Antibodies
Epidermal Growth Factor Receptor
Incidence
Risk Reduction Behavior
PubMed
Confidence Intervals
Therapeutics

Keywords

  • Adverse events
  • Anti-egfr monoclonal antibodies
  • Cetuximab
  • Colorectal cancer
  • Diarrhoea
  • Meta-analysis
  • Mucositis
  • Panitumumab
  • Pharmacovigilance
  • Systematic review

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens : A meta-analysis of 18 randomized controlled clinical trials. / Miroddi, Marco; Sterrantino, Carmelo; Simonelli, Ilaria; Ciminata, Giorgio; Phillips, Robert S.; Calapai, Gioacchino.

In: Critical Reviews in Oncology/Hematology, Vol. 96, No. 2, 25.10.2014, p. 355-371.

Research output: Contribution to journalArticle

Miroddi, Marco ; Sterrantino, Carmelo ; Simonelli, Ilaria ; Ciminata, Giorgio ; Phillips, Robert S. ; Calapai, Gioacchino. / Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens : A meta-analysis of 18 randomized controlled clinical trials. In: Critical Reviews in Oncology/Hematology. 2014 ; Vol. 96, No. 2. pp. 355-371.
@article{69bf2c26bb5a4a8b82c9730db0b18709,
title = "Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials",
abstract = "The anti-Epidermal Growth Factor Receptor monoclonal antibodies (anti-EGFR MoAbs) are beneficial in the treatment of wild type (WT) KRAS colorectal cancer, but are burdened by serious toxicities. We conducted a systematic review and meta-analysis to determine incidence and relative risk (RR) of severe and life-threatening diarrhoea and mucositis in colorectal cancer patients and WT-KRAS subpopulation. PubMed and Embase were searched for trials comparing the same therapeutic regimens with or without anti-EGFR for colorectal cancer. Data on severe and life-threatening diarrhoea and mucositis were extracted from 18 studies involving 13,382 patients. Statistical analyses calculated incidence of AEs, RRs and 95{\%} confidence intervals by using either random or fixed effects models. Patients receiving anti-EGFR MoAbs showed an increased risk of diarrhoea (RR: 1.66, CI 1.52-1.80) and mucositis (RR: 3.44, CI 2.66-4.44). The risk was similar among WT-KRAS patients. Prevention and risk reduction strategies of these AEs are mandatory to optimize clinical outcomes.",
keywords = "Adverse events, Anti-egfr monoclonal antibodies, Cetuximab, Colorectal cancer, Diarrhoea, Meta-analysis, Mucositis, Panitumumab, Pharmacovigilance, Systematic review",
author = "Marco Miroddi and Carmelo Sterrantino and Ilaria Simonelli and Giorgio Ciminata and Phillips, {Robert S.} and Gioacchino Calapai",
year = "2014",
month = "10",
day = "25",
doi = "10.1016/j.critrevonc.2015.06.004",
language = "English",
volume = "96",
pages = "355--371",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens

T2 - A meta-analysis of 18 randomized controlled clinical trials

AU - Miroddi, Marco

AU - Sterrantino, Carmelo

AU - Simonelli, Ilaria

AU - Ciminata, Giorgio

AU - Phillips, Robert S.

AU - Calapai, Gioacchino

PY - 2014/10/25

Y1 - 2014/10/25

N2 - The anti-Epidermal Growth Factor Receptor monoclonal antibodies (anti-EGFR MoAbs) are beneficial in the treatment of wild type (WT) KRAS colorectal cancer, but are burdened by serious toxicities. We conducted a systematic review and meta-analysis to determine incidence and relative risk (RR) of severe and life-threatening diarrhoea and mucositis in colorectal cancer patients and WT-KRAS subpopulation. PubMed and Embase were searched for trials comparing the same therapeutic regimens with or without anti-EGFR for colorectal cancer. Data on severe and life-threatening diarrhoea and mucositis were extracted from 18 studies involving 13,382 patients. Statistical analyses calculated incidence of AEs, RRs and 95% confidence intervals by using either random or fixed effects models. Patients receiving anti-EGFR MoAbs showed an increased risk of diarrhoea (RR: 1.66, CI 1.52-1.80) and mucositis (RR: 3.44, CI 2.66-4.44). The risk was similar among WT-KRAS patients. Prevention and risk reduction strategies of these AEs are mandatory to optimize clinical outcomes.

AB - The anti-Epidermal Growth Factor Receptor monoclonal antibodies (anti-EGFR MoAbs) are beneficial in the treatment of wild type (WT) KRAS colorectal cancer, but are burdened by serious toxicities. We conducted a systematic review and meta-analysis to determine incidence and relative risk (RR) of severe and life-threatening diarrhoea and mucositis in colorectal cancer patients and WT-KRAS subpopulation. PubMed and Embase were searched for trials comparing the same therapeutic regimens with or without anti-EGFR for colorectal cancer. Data on severe and life-threatening diarrhoea and mucositis were extracted from 18 studies involving 13,382 patients. Statistical analyses calculated incidence of AEs, RRs and 95% confidence intervals by using either random or fixed effects models. Patients receiving anti-EGFR MoAbs showed an increased risk of diarrhoea (RR: 1.66, CI 1.52-1.80) and mucositis (RR: 3.44, CI 2.66-4.44). The risk was similar among WT-KRAS patients. Prevention and risk reduction strategies of these AEs are mandatory to optimize clinical outcomes.

KW - Adverse events

KW - Anti-egfr monoclonal antibodies

KW - Cetuximab

KW - Colorectal cancer

KW - Diarrhoea

KW - Meta-analysis

KW - Mucositis

KW - Panitumumab

KW - Pharmacovigilance

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84955170594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955170594&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.06.004

DO - 10.1016/j.critrevonc.2015.06.004

M3 - Article

AN - SCOPUS:84955170594

VL - 96

SP - 355

EP - 371

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -